UK Alopecia Therapeutics (Hair Loss) Market Sample Report 2022 to 2030

The UK Alopecia (Hair Loss) Therapeutics Market was valued at US $213 Mn in 2022, and is predicted to grow at (CAGR) of 5.5% from 2023 to 2030, to US $327 Mn by 2030. The key drivers of this industry include the surge in the prevalence of Alopecia (hair loss), increased disposable income, technological advancements, and others. The industry is primarily dominated by players such as Johnson & Johnson, Eli Lilly, Merck, Cipla, Sun Pharmaceuticals, Allergan, and Pfizer, among others.

1. UK Alopecia (Hair Loss)
Therapeutics Market
Analysis
Sample Report
July 2024

2. This report presents a strategic analysis of the UK Alopecia (Hair
Loss) Therapeutics Market and a forecast for its development in the
medium and long term. It provides a comprehensive overview of the
market value, dynamics, segmentation, main players, growth and
demand drivers, challenges & future outlook, etc. This is one of the
most comprehensive reports about the UK Alopecia (Hair Loss)
Therapeutics Market, and offers unmatched value, accuracy, and
expert insights.

3. 3 A Sample Report on UK Alopecia (Hair Loss) Therapeutics Market Analysis I Confidential
Report Attribute Details
Number of Pages 70-80
Base Year for Estimation 2023
Forecast Period 2024-2030
Report Coverage
Market Overview, Size & Forecasting, Market Segmentation, Growth Factors and Trends, Competitive
Landscape, Key Company Profiles, Government Policies, Regulatory Landscape, Reimbursement
Scenario
Quantitative Units Revenue in USD Million/Billion (Mn/Bn)
Currency Conversion 1 GBP = 1.28 USD
Research Approach Secondary Research (90%), Primary Research (10%)
Report Scope

4. 4 A Sample Report on UK Alopecia (Hair Loss) Therapeutics Market Analysis I Confidential
CONTENT PG. NO.
1. Market Overview 08-15
1.1 UK Alopecia (Hair Loss) Therapeutics Market Overview
1.2 Alopecia (Hair Loss) Therapeutics Market Overview: Global
1.3 Economic Overview: UK
1.4 Alopecia (Hair Loss) Therapeutics Market Overview: UK
1.5 Healthcare Overview: UK
1.6 Budget of UK Government for Public Insurance
1.7 Top Developments in UK
2. Epidemiology 16-18
2.1 Prevalence
2.2 Physiological Impact of Alopecia
3. Market Sizing and Forecasting 19-24
3.1 UK Alopecia (Hair Loss) Therapeutics Market Size and Forecasts
Table of Content

5. 5 A Sample Report on UK Alopecia (Hair Loss) Therapeutics Market Analysis I Confidential
CONTENT PG. NO.
3.2 Snapshot of UK Alopecia (Hair Loss) Therapeutics Market Segmentation
3.2.1 Market Segmentation: By Disease Type
3.2.2 Market Segmentation: By Gender
3.2.3 Market Segmentation: By End User
4. Market Dynamics 25-30
4.1 Market Growth Drivers
4.2 Market Growth Restraints
5. Competitive Landscape 31-38
5.1 Key Players in UK Alopecia (Hair Loss) Therapeutics Market
6. Regulatory and Reimbursement Landscape 39-43
6.1 Regulatory Landscape in UAE
6.2 Reimbursement Scenario in UK
6.3 Reimbursement Process
Table of Content

6. 6 A Sample Report on UK Alopecia (Hair Loss) Therapeutics Market Analysis I Confidential
CONTENT PG. NO.
6.1 Regulatory Landscape in UAE
6.2 Reimbursement Scenario in UK
6.3 Reimbursement Process
Table of Content

7. UK Alopecia (Hair Loss) Therapeutics Market Analysis
1. Market Overview

8. ▪Alopecia, which is defined as sporadic or diffuse, transient or permanent, affecting people of all
ages and genders, is a condition that affects a significant number of people
▪Condition, stemming from various causes, including heightened stress levels, diabetes, poor
nutrition, and environmental influences, can induce significant distress among patients, influencing
their overall quality of life
▪Male pattern baldness is more common and often more severe than female pattern hair loss
Signs and Symptoms of Alopecia are:
▪Gradual thinning on top of head: This is the most common type of hair loss, affecting people as they age. In
men, hair often begins to recede at the hairline on the forehead. Women typically have a broadening of the part
in their hair
▪Circular or patchy bald spots:Some people lose hair in circular or patchy bald spots on the scalp, beard or
eyebrows. Your skin may become itchy or painful before the hair falls out
▪Sudden loosening of hair: Physical or emotional shock can cause hair to loosen
▪Brittle and red fingernails and toenails: are sign of alopecia due to micronutrients deficiency
1.1 Alopecia (Hair Loss) Therapeutics Market Analysis
Illustrative

9. 9 A Sample Report on UK Alopecia (Hair Loss) Therapeutics Market Analysis I Confidential
563
580
599
620
642
665
689
715
739
761
779
805
2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023
65+ Population in the World 2012-2021 (In Mn)
1.2 Alopecia (Hair Loss) Therapeutics Market Overview: Global (1/2)
805 Mn
Population of people
aged above 60 year
in 2023
2.3%
Fertility rate as of
2023
5% Mn
Prevalence of
depression rate as of
2023
33%
Population affected
by Anemia
worldwide as of
2023
Illustrative

10. 10 A Sample Report on UK Alopecia (Hair Loss) Therapeutics Market Analysis I Confidential
UK Alopecia (Hair Loss)
Therapeutics Market
~$xx Bn Market
Illustrative
1.2 Alopecia (Hair Loss) Therapeutics Market Overview: Global (2/2)

11. 11 A Sample Report on UK Alopecia (Hair Loss) Therapeutics Market Analysis I Confidential
17%
66%
19%
64.1
64.6
65.1
65.6
66
66.4
66.8
6767
67.7
68.3
20132014201520162017201820192020202120222023
Population of UK, (In Mn)
2%
3%
2%2%
3%
1%
2%
-10%
9%
4% 0%
20132014201520162017201820192020202120222023
GDP Growth of UK, (In %)
Population Split (2023)
0-14
15-64
65+
49%
51%
By Age GroupBy Gender
▪UK is an aging country, as it’s median age is 40.7 years which is
higher than global median age
▪Country's population’s global share is 0.85% and it is increasing
at a rate of 0.3%
▪Life expectancy of female is 75 years and for male it is 70 years
▪Currently 84.4% of population is urban in UK
▪Top 3 largest cities are UK is London, Manchester and Leeds
Illustrative
1.3 Economic Overview: UK
Male
Female

12. 12 A Sample Report on UK Alopecia (Hair Loss) Therapeutics Market Analysis I Confidential
10.7
11.0
11.3 11.4
11.7
11.9
12.1
12.3
12.5 12.6 12.6
13.2
2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023
65+ Population in the UK 2012-2021 (In Mn)
1.4 Alopecia (Hair Loss) Therapeutics Market Overview: UK
13.2 Mn
Population of people
aged 60 years and
older in 2030
1.6
Fertility rate as of
2023
16%
Prevalence of
depression in age
group 16-29 in 2023
11%
Population in UK are
diagnosed with
anemia in 2023
Illustrative

13. 13 A Sample Report on UK Alopecia (Hair Loss) Therapeutics Market Analysis I Confidential
1.5 Healthcare Overview: UK
Public Healthcare
Structure
›Funding: Predominantly funded through general taxation
and National Insurance contributions
›Administration: The Department of Health and Social
Care oversees the NHS in England. Scotland, Wales, and
Northern Ireland have their own NHS systems
›Services: The NHS covers a wide range of services,
including primary care, hospital care, emergency services,
maternity care, mental health services, and specialist care
Access
›Eligibility: All UK residents are eligible for NHS care.
This includes citizens, permanent residents, and some
visa holders
›Cost: Most NHS services are free at the point of use. This
includes GP visits, hospital care, and emergency services.
Some services require co-payments
Private Healthcare
Structure
›Providers: Includes private hospitals, clinics, and
specialists
›Funding: Private healthcare covers a wide range of
services, including hospital care, specialist consultations,
diagnostics, and elective procedures.
›Services: Private health insurance is relatively common,
especially among higher-income groups and through
employer-sponsored schemes.
Access
›Insurance: Private health insurance is common, covering
services that are either not fully funded or not available in
the public system
›Cost: Patients often face higher out-of-pocket expenses
compared to NHS care. Insurance can offset these costs
Illustrative

14. 14 A Sample Report on UK Alopecia (Hair Loss) Therapeutics Market Analysis I Confidential
Proposed Budget By Category
Outlays 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2022-31
In Billions Of Dollars
Medicare
$769 $709 $766 $841 $840 $947 $1,014 $1,085 $1,227 $1,178 $1,325 $1,412 $10,633
As % Of GDP 3.7% 3.2% 3.3% 3.4% 3.3% 3.6% 3.7% 3.8% 4.1% 3.8% 4.1% 4.2% 3.7%
▪National Health Expenditures (NHE) grew 2.7% to $4.3 Tn in 2021, or $12,914 per person, and accounted for 18.3% of Gross Domestic Product (GDP)
▪Medicare spending grew 8.4% to $900.8 Bn in 2021, or 21% of total NHE
▪Private health insurance spending grew 5.8% to $1,211.4 Bn in 2021, or 28% of total NHE
▪Out of pocket spending grew 10.4% to $433.2 Bn in 2021, or 10% of total NHE
▪Other Third Party Payers and Programs and Public Health Activity spending declined 20.7% in 2021 to $596.6 Bn, or 14% of total NHE
▪Hospital expenditures grew 4.4% to $1,323.9 Bn in 2021, slower than the 6.2% growth in 2020
▪Physician and clinical services expenditures grew 5.6% to $864.6 Bn in 2021, slower growth than the 6.6% in 2020
▪Prescription drug spending increased 7.8% to $378.0 Bn in 2021, faster than the 3.7% growth in 2020
▪Largest shares of total health spending were sponsored by the federal government (34%) and the households (27%). The private business share of health spending
accounted for 17% of total health care spending, state and local governments accounted for 15%, and other private revenues accounted for 7%
Illustrative
1.6 Budget of UK Government for Public Insurance

15. 15 A Sample Report on UK Alopecia (Hair Loss) Therapeutics Market Analysis I Confidential
Company Name Type Year Key Pointers
Acquisition Feb, 2024
▪AstraZeneca on the leading Pharm company in UK successful completed
acquisition of Icosavax, Inc., a US-based clinical-stage biopharmaceutical
company focused on developing differentiated, high-potential vaccines
using an innovative, protein virus-like particle (VLP) platform
▪Acquisition will build on AstraZeneca’s expertise in respiratory syncytial
virus (RSV), strengthening AstraZeneca’s Vaccines & Immune Therapies
late-stage pipeline
Acquisition Feb, 2024
▪GSK leading pharmaceutical company in UK has completed the
acquisition of Aiolos Bio (Aiolos), a clinical-stage biopharmaceutical
company focused on addressing the unmet treatment needs of patients
with respiratory and inflammatory conditions.
▪Acquisition of Aiolos includes AIO-001, a potentially best-in-class, long-
acting anti-thymic stromal lymphopoietin (TSLP) monoclonal antibody
ready to enter phase II clinical development for the treatment of adult
patients with asthma
Latest Deals in UK
Illustrative
1.7 Top Developments in UK

16. UK Alopecia (Hair Loss) Therapeutics Market Analysis
2. Epidemiology

17. 17 A Sample Report on UK Alopecia (Hair Loss) Therapeutics Market Analysis I Confidential
Illustrative
2.1 Prevalence
Androgenetic Alopecia: Affects up to 50% of men by age 50, Impacts about 50% of women over their lifetime. In the UK, an estimated 8
million women experience hair loss, this condition is known as male-pattern baldness and female-pattern baldness. It usually occurs
gradually and in predictable patterns, a receding hairline and bald spots in men and thinning hair along the crown of the scalp in women.
Hormonal changes and medical conditions are one of the leading cause of it
Alopecia Areata: Affects approximately 1-2% of the UK population. Lifetime risk is estimated at around 2%. In the UK, about 100,000
people are diagnosed each year, people with the disease are usually healthy and have no other symptoms. Alopecia areata typically
begins with sudden loss of round or oval patches of hair on the scalp, but any part of the body may be affected, such as the beard area in
men, or the eyebrows or eyelashes
Cicatricial (Scarring) Alopecia: Cicatricial Alopecia is one of the least common types of alopecia in UK. Accounts for about 3-7% of hair
loss cases seen in dermatology clinics, generally, cicatricial alopecia is caused byinflammation, which damages the hair follicle. Damage
can also stem from a trauma such as a burn or serious infection. The inflammation can involve different types of cells, including
lymphocytes, natural killer cells, or several cell types

18. 18 A Sample Report on UK Alopecia (Hair Loss) Therapeutics Market Analysis I Confidential
Illustrative
2.2 Physiological Impact of Alopecia
Male Hair Loss Statistics
▪Also known as androgenetic alopecia, is a highly
prevalent condition that affects approximately
85% of all men by the age of 50
▪Genetic nature of male pattern baldness stems
from the hair follicles being sensitive and reacting
to dihydrotestosterone (DHT), a by-product of
testosterone
▪When this happens, high levels of DHT in the
body shrink the hair follicles, shortening the hair
growth cycle and causing hair loss
▪It leads to a receding hairline, thinning on the
crown and temples, and complete baldness
without intervention
Female Hair Loss Statistics
▪Approximately 40% of women show signs of hair
loss by 50, with less than 45% of women reaching
80 with a full head of hair, According to some
studies, women with high levels of stress are 11
times more likely to experience hair loss
▪Female hair losshas become a growing issue in
the UK since the recent stresses associated with
factors like the pandemic, cost-of-living crisis and
social media, with almost 90% of requests forhair
loss treatmentnow coming from women
▪Female pattern baldness is also highly prevalent
in post-menopausal women, reduces oestrogen
can be a leading cause

19. UK Alopecia (Hair Loss) Therapeutics Market Analysis
3. Market Size and Forecasting

20. 20 A Sample Report on UK Alopecia (Hair Loss) Therapeutics Market Analysis I Confidential
2023 2024F 2025F 2026F 2027F 2028F 2029F 2030F
UK Alopecia (Hair Loss) Therapeutics
Market Forecast, 2023-2030
2023 2024 2025 2026 2027 2028 2029 2030
Major Markets Patient ($Mn) 2.74 2.82 2.90 2.94 2.98 3.02 3.07 3.12
UK Patient Size ($Bn) 0.51 0.61 0.68 0.69 0.70 0.71 0.72 0.73
% of Patients 18.75% 21.70% 23.56% 23.45% 23.42% 23.39% 23.34% 23.45%
Global Market Size ($Bn) 3,620 3,780 3,950 4,128 4,314 4,508 4,711 4,937
UK Market Size ($Bn) 61 74 84 87 91 95 99 106
Illustrative
3.1 UK Alopecia (Hair Loss) Therapeutics Market Size and Forecasts

21. 21 A Sample Report on UK Alopecia (Hair Loss) Therapeutics Market Analysis I Confidential
▪In this section you will get an understanding of the segmentations which will cover the UK Alopecia (Hair Loss) Therapeutics Market
▪In order to obtain access to all of the information that you are seeking, you will need to purchase the final report
Disease Type
Alopecia Areata
Cicatricial Alopecia
Androgenetic Alopecia
Others
Gender
Male
Female
End User
Hospital
Physician’s Clinics
Others
Illustrative
3.2 Snapshot of UK Alopecia (Hair Loss) Therapeutics Market Segmentation

22. 22 A Sample Report on UK Alopecia (Hair Loss) Therapeutics Market Analysis I Confidential
▪Please be aware that this sample report is
intended to provide you with a brief
overview of the kind of information and
analysis that will be presented in the final
report
▪In order to obtain access to all of the
information that you are seeking, you will
need to purchase the final report
▪Final report will be comprehensive and
detailed, and it will include data, analysis,
trends, and other relevant information
related to the topic or subject matter of
interest
UK Alopecia (Hair Loss) Therapeutics Market Share, By Disease Type
(2023)
Alopecia
Areata
Cicatricial
Alopecia
Androgenic
Alopecia
Others
Illustrative
3.2.1 Market Segmentation: By Disease Type

23. 23 A Sample Report on UK Alopecia (Hair Loss) Therapeutics Market Analysis I Confidential
▪Please be aware that this sample report is
intended to provide you with a brief
overview of the kind of information and
analysis that will be presented in the final
report
▪In order to obtain access to all of the
information that you are seeking, you will
need to purchase the final report
▪Final report will be comprehensive and
detailed, and it will include data, analysis,
trends, and other relevant information
related to the topic or subject matter of
interest
UK Alopecia (Hair Loss) Therapeutics Market Share, By Gender
(2023)
Female
Male
Illustrative
3.2.2 Market Segmentation: By Therapeutic Type

24. 24 A Sample Report on UK Alopecia (Hair Loss) Therapeutics Market Analysis I Confidential
▪Please be aware that this sample report is
intended to provide you with a brief
overview of the kind of information and
analysis that will be presented in the final
report
▪In order to obtain access to all of the
information that you are seeking, you will
need to purchase the final report
▪Final report will be comprehensive and
detailed, and it will include data, analysis,
trends, and other relevant information
related to the topic or subject matter of
interest
UK Alopecia (Hair Loss) Therapeutics Market Share, By End User
(2023)
Hospitals
Physicians
Clinics
Others
Illustrative
3.2.3 Market Segmentation: By End User

25. UK Alopecia (Hair Loss) Therapeutics Market Analysis
4. Market Dynamics

26. 26 A Sample Report on UK Alopecia (Hair Loss) Therapeutics Market Analysis I Confidential
Illustrative
4.1.1
Surge in prevalence
of Alopecia is
boosting market
growth rate
4.1.2
Development of new
hair restoration
techniques and
treatments is boosting
market growth
4.1.3
High-stress lifestyles
contributing to hair
loss and thus boosting
the market growth
4.2.1
Expensive
treatment and
medication can
downsize the
market growth
4.2.2
Strict regulations on
new hair loss
treatments and
procedures is
hindering market
4. Snapshot Of Market Growth Drivers And Restraints

27. 27 A Sample Report on UK Alopecia (Hair Loss) Therapeutics Market Analysis I Confidential
Illustrative
▪Please be aware that this sample report is intended to provide you with a
brief overview of the kind of information and analysis that will be
presented in the final report
▪In order to obtain access to all of the information that you are seeking,
you will need to purchase the final report
▪Final report will be comprehensive and detailed, and it will include data,
analysis, trends, and other relevant information related to the topic or
subject matter of interest
4.1 Market Growth Drivers
4.1.1 Surge in prevalence of Alopecia is boosting market growth rate
Increasing prevalence of alopecia (%)
2010 2022 2030

28. 28 A Sample Report on UK Alopecia (Hair Loss) Therapeutics Market Analysis I Confidential
▪Please be aware that this sample report is intended to provide you with a
brief overview of the kind of information and analysis that will be
presented in the final report
▪In order to obtain access to all of the information that you are seeking,
you will need to purchase the final report
▪Final report will be comprehensive and detailed, and it will include data,
analysis, trends, and other relevant information related to the topic or
subject matter of interest
2010 2022 2030
Illustrative
4.1 Market Growth Drivers
4.1.2 Development of new hair restoration techniques and treatments is boosting market growth
Increasing Investment In New Technology
And Innovation ($Mn)

29. 29 A Sample Report on UK Alopecia (Hair Loss) Therapeutics Market Analysis I Confidential
▪Please be aware that this sample report is intended to provide you with a
brief overview of the kind of information and analysis that will be
presented in the final report
▪In order to obtain access to all of the information that you are seeking,
you will need to purchase the final report
▪Final report will be comprehensive and detailed, and it will include data,
analysis, trends, and other relevant information related to the topic or
subject matter of interest
Illustrative
4.1 Market Growth Drivers
4.1.3 High-stress lifestyles contributing to hair loss and thus boosting the market growth
Increase In High-stress Lifestyles Leading to
Alopecia (%)
2010 2022 2030

30. 30 A Sample Report on UK Alopecia (Hair Loss) Therapeutics Market Analysis I Confidential
4.2.1 Expensive treatment and medication can downsize
the market growth
▪Please be aware that this sample report is intended to provide
you with a brief overview of the kind of information and analysis
that will be presented in the final report
▪In order to obtain access to all of the information that you are
seeking, you will need to purchase the final report
▪Final report will be comprehensive and detailed, and it will
include data, analysis, trends, and other relevant information
related to the topic or subject matter of interest
4.2.2 Strict regulations on new hair loss treatments and
procedures is hindering market
▪Please be aware that this sample report is intended to provide
you with a brief overview of the kind of information and analysis
that will be presented in the final report
▪In order to obtain access to all of the information that you are
seeking, you will need to purchase the final report
▪Final report will be comprehensive and detailed, and it will
include data, analysis, trends, and other relevant information
related to the topic or subject matter of interest
Our analysis will thoroughly investigate the key restraints that may significantly impact business
operations and growth.
Illustrative
4.2 Market Growth Restraints

31. UK Alopecia (Hair Loss) Therapeutics Market Analysis
5. Competitive Landscape

32. 32 A Sample Report on UK Alopecia (Hair Loss) Therapeutics Market Analysis I Confidential
▪Here is the list of top 10 companies which
will cover in the final report
▪Each company will have slides for
oOverview
oKey details
oOfferings
oName of products
oRecent activities/ Press Coverage
oDistribution and Vendor Partners
oMergers, Acquisitions and
Collaboration
oFinancials
▪If there are specific companies that you
would like to be included in the report,
please let us know via email
▪In order to obtain access to all of the
information that you are seeking, you will
need to purchase the final report
Pfizer1 GSK6
Cipla2 Theradome7
Sun Pharma3
iRestore Hair Growth
system
8
Dr Reddy's4 Oxford Biolabs9
Allergan5 Accord Healthcare10
Illustrative
Global Player Local Player
5.1 Key Players in UK Alopecia (Hair Loss) Therapeutics Market

33. 33 A Sample Report on UK Alopecia (Hair Loss) Therapeutics Market Analysis I Confidential
Founded In: 1849
HQ: New York, US
Type: Private
Revenue: $58.5 Bn (Global)
Website: Pfizer.com
▪Pfizer is a global pharmaceutical corporation with a significant
presence in the United Arab Emirates. It is one of the leading
providers of innovative medicines, vaccines, and consumer
healthcare products in the region
▪Pfizer has been operating in the Middle East for over 60 years, with
the UAE serving as a key market and regional hub its operations
▪Pfizer UAE supports various health awareness campaigns and
educational programs for healthcare professionals in the country
Area of Focus
➢Oncology
➢Inflammation and Immunology
➢Rare Diseases
➢Vaccines
Recent Activity / Press Coverage
▪June 1, 2024 — Pfizer announced detailed overall survival (OS) results from the Phase 3 ECHELON-3 study of ADCETRIS(brentuximab vedotin) in
combination with lenalidomide and rituximab for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). The study
showed that the ADCETRIS combination reduced patients’ risk of death by 37% compared to placebo in combination with lenalidomide and rituximab.
The overall survival benefit was consistent across levels of CD30 expression
▪April 22, 2024 — Pfizer announced that the European Commission (EC) has granted marketing authorization for EMBLAVEO

(aztreonam-avibactam) for
the treatment of adult patients with complicated intra-abdominal infections (cIAI), hospital-acquired pneumonia (HAP), including ventilator-associated
pneumonia (VAP), and complicated urinary tract infections (cUTI), including pyelonephritis. It is also indicated for the treatment of infections due to
aerobic Gram-negative organisms in adult patients with limited treatment options
▪March 13, 2024 — Pfizer announced that the European Commission (EC) has granted marketing authorization for the company’s 20-valent
pneumococcal conjugate vaccine, marketed in the European Union under the brand name PREVENAR 20, for active immunization for the prevention of
invasive disease, pneumonia and acute otitis media caused byStreptococcus pneumoniaein infants, children and adolescents from 6 weeks to less
than 18 years of age
5.1.1 Pfizer (Continued)

34. 34 A Sample Report on UK Alopecia (Hair Loss) Therapeutics Market Analysis I Confidential
Company Name Type Year Key Pointers
Drug Approval Nov, 2023
▪The Medicines and Healthcare products Regulatory Agency (MHRA)
authorised a new medicine called Litfulo (ritlecitinib), an enzyme inhibitor
treatment for severe alopecia areata in patients 12 years and older
▪Alopecia areata is a disease where the body’s own immune system
attacks hair follicles, causing inflammation that leads to hair loss on the
scalp, face and/or other parts of the body
Acquisition Mar, 2023
▪Pfizer announced its acquisition of Seagen Inc. for approximately $43 Bn
▪Seagen is a leading developer of antibody-drug conjugates (ADCs), a
type of targeted cancer therapy
▪This deal gives Pfizer access to Seagen's four approved cancer therapies
and a pipeline of promising candidates
▪It's one of the largest pharmaceutical acquisitions in recent years,
demonstrating Pfizer's commitment to expanding its cancer treatment
portfolio
Latest Deals in Pfizer
Illustrative
5.1.1 Pfizer (Continued)

35. 35 A Sample Report on UK Alopecia (Hair Loss) Therapeutics Market Analysis I Confidential
▪Please be aware that this sample report is
intended to provide you with a brief
overview of the kind of information and
analysis that will be presented in the final
report
▪In order to obtain access to all of the
information that you are seeking, you will
need to purchase the final report
▪Final report will be comprehensive and
detailed, and it will include data, analysis,
trends, and other relevant information
related to the topic or subject matter of
interest
2020202120222023F2024F2025F2026F2027F2028F2029F2030F
Revenues ($Bn), 2020-2030
Breakdown of Net Revenue by Segment, 2023
1 2 3 4
Illustrative
5.1.1 Pfizer (Continued)

36. 36 A Sample Report on UK Alopecia (Hair Loss) Therapeutics Market Analysis I Confidential
Founded In:
HQ:
Type:
Revenue:
Website:
Offerings
Recent Activity / Press Coverage
5.1.1 Company 2
Illustrative

37. 37 A Sample Report on UK Alopecia (Hair Loss) Therapeutics Market Analysis I Confidential
Company Name Type Year Key Pointers
Latest Deals in CompanyName
Illustrative
5.1.1 Company 2 (Continued)

38. 38 A Sample Report on UK Alopecia (Hair Loss) Therapeutics Market Analysis I Confidential
▪Please be aware that this sample report is
intended to provide you with a brief
overview of the kind of information and
analysis that will be presented in the final
report
▪In order to obtain access to all of the
information that you are seeking, you will
need to purchase the final report
▪Final report will be comprehensive and
detailed, and it will include data, analysis,
trends, and other relevant information
related to the topic or subject matter of
interest
2020202120222023F2024F2025F2026F2027F2028F2029F2030F
Revenues ($Bn), 2020-2030
Breakdown of Net Revenue by Segment, 2023
1 2 3 4
Illustrative
5.1.1 Company 2 (Continued)

39. UK Alopecia (Hair Loss) Therapeutics Market Analysis
6. Regulatory and Reimbursement Landscape

40. 40 A Sample Report on UK Alopecia (Hair Loss) Therapeutics Market Analysis I Confidential
Department of Health and Social Care (DHSC), is the main governmental body responsible for health policy in the UK under which Medicines
and Healthcare products Regulatory Agency (MHRA) regulates the pharmaceutical industry. Its key governmental agencies responsible for the
regulation of various activities are:
▪National Institute for Health and Care Excellence (NICE):Provides national guidance and advice to improve health and social care,
assesses the clinical and cost-effectiveness of new treatments
▪Care Quality Commission (CQC): In England, the CQC is the independent regulator for the quality and safety of care. This includes the
care provided by the NHS, local authorities, independent providers and voluntary organizations in registered settings
▪NHS: NHS is the publicly funded healthcare system that provides medical services to the UK population. NHS plays a central regulatory,
service delivery, and workforce development role in the UK healthcare system
▪British Pharmacopoeia Commission: Responsible for the British Pharmacopoeia, which specifies quality standards for UK medicinal
substances
▪Advisory Board on the Registration of Homeopathic Products: Advisory board advises on the safety and quality of homeopathic
medicines when there’s an application for registration, marketing authorisationor licenceof right
▪Clinical Practice Research Datalink (CPRD) Research Data Governance (RDG) Process: Independent scientific and patient advice on
research-related requests to access CPRD data via the non-statutory Independent Scientific Advisory Committee was established in2006,
and superseded in June 2021 by the RDG Process comprisingExpert Review Committees (ERCs)and theCentral Advisory Committee
(CAC)
▪Commission on Human Medicines: Commission on Human Medicines (CHM) advises ministers on the safety, efficacy and quality of
medicinal products
Illustrative
Regulatory Authorities With Jurisdiction Over Drugs, Biologicals, And Medical Devices In UK
6.1 Regulatory Landscape in UK

41. 41 A Sample Report on UK Alopecia (Hair Loss) Therapeutics Market Analysis I Confidential
Key Legislation
Key legislations for the drug industry in the UK is Medicines and Healthcare products Regulatory Agency (MHRA) founded in 2003. Other
important acts are Medicines Act 1968 (as amended), Human Medicines Regulations 2012, Misuse of Drugs Act 1971, Psychoactive Substances
Act 2016, Medical Devices Regulations 2002 (as amended) etc
Authorization
The authorization process for new drugs in the UK involves the following steps:
▪Pre-submission: Determine the type of product and appropriate authorization route (e.g., national procedure, mutual recognition,
decentralized procedure, or centralized EU procedure
▪Submission of application: Submit a marketing authorization application (MAA) to the MHRA via the Common European Submission
Platform (CESP). For centralized procedures, submit to the European Medicines Agency (EMA)
▪Validation: MHRA validates the application to ensure all required information is present
▪Scientific assessment: MHRA experts evaluate the quality, safety, and efficacy data. This typically takes 210 days, excluding clock
stops for applicant responses
▪Commission on Human Medicines (CHM) review: For some applications, the CHM provides additional expert advice
▪Decision: MHRA makes a decision to grant or refuse the marketing authorization
▪Post-authorization: Ongoing pharmacovigilance and periodic safety update reports are required
Illustrative
Regulatory Framework For The Authorization, Pricing, And Reimbursement Of Drugs
6.2 Reimbursement Scenario in UK

42. 42 A Sample Report on UK Alopecia (Hair Loss) Therapeutics Market Analysis I Confidential
Coverage Penetration (% Total Population) Source of Funding
Spend on Healthcare (%of Current Health Expenditure)
Reimbursement Market Trends
Public healthcare coverage is provided by the government and includes
programs like Medicare and Medicaid
Medicare is a federal program that provides healthcare coverage to individuals
who are 65 years of age or older, as well as certain younger people with
disabilities
▪Shift towards value-based care has been a significant trend in UK healthcare system, with payers and providers increasingly focused on improving patient outcomes
and reducing costs
▪This has led to the development of alternative payment models such as accountable care organizations (ACOs) and bundled payment arrangements, which
incentivize providers to deliver high-quality, cost-effective care
38.9% 37.1% 35.6% 32.5% 31.5%
44.0%
46.0% 47.7%
51.0% 51.8%
2017 2018 2019 2020 2021 2022 2023
Government Expenditure
Private Health Insurance
Out of Pocket
Other
NA NA
100% 100% 100% 100% 100%
xx
xx xx
xx xx
2019 2020 2021 2022 2023
Public Healthcare
Coverage
Private Coverage
6.3% 4.08% 5.1% 3.8% 2.2% 2.4% 3.6% GDP Growth (yoy)
14.7% 11.3% 15.5% 7.5% 4.2% NA NA HC Spend Growth (yoy)
Illustrative
6.2 Reimbursement Scenario in UK (Continued)

43. 43 A Sample Report on UK Alopecia (Hair Loss) Therapeutics Market Analysis I Confidential
The reimbursement process in UK healthcare system can be complex and can vary depending on the type of healthcare service, the
healthcare provider, and the insurance coverage. Here are the general steps involved in the reimbursement process:
▪Service or Treatment Provided: The healthcare provider performs a service or treatment for the patient
▪Billing: The healthcare provider submits a claim to the insurance company or other payer, requesting reimbursement for the
service provided
▪Adjudication: The insurance company or other payer reviews the claim to determine whether it meets the criteria for
reimbursement. This can involve verifying the patient's eligibility, reviewing the treatment provided, and checking for any potential
errors or fraud
▪Payment: If the claim is approved, the insurance company or other payer reimburses the healthcare provider for the service
provided, based on the negotiated payment rates or fee schedule
▪Patient Responsibility: Depending on the patient's insurance coverage, they may be responsible for paying a portion of the cost
of the service, such as deductibles, co-payments, or co-insurance
In order to obtain access to all of the information that you are seeking, you will need to purchase the final report
Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the
topic or subject matter of interest
Illustrative
6.3 Reimbursement Process

44. 44 A Sample Report on UK Alopecia (Hair Loss) Therapeutics Market Analysis I Confidential
The reimbursement process in UK healthcare system can be complex and
can vary depending on the type of healthcare service, the healthcare
provider, and the insurance coverage. Here are the general steps involved
in the reimbursement process:
▪Service or Treatment Provided: The healthcare provider performs a
service or treatment for the patient
▪Billing: The healthcare provider submits a claim to the insurance
company or other payer, requesting reimbursement for the service
provided
▪Adjudication: The insurance company or other payer reviews the claim
to determine whether it meets the criteria for reimbursement. This can
involve verifying the patient's eligibility, reviewing the treatment
provided, and checking for any potential errors or fraud
▪Payment: If the claim is approved, the insurance company or other
payer reimburses the healthcare provider for the service provided,
based on the negotiated payment rates or fee schedule
MHRA
Private Payers Public Payers
Health Technology Assessment
PaymentCoverageCoding
Coding depends on availability code while coverage and
payment process decisions are made through an HTA.
Market Authorization
1 32
Illustrative
6.3 Reimbursement Process (Continued)

45. A division
of

46. Life-sciences Market Research
Reports you can trust
www. insig hts10. com
www.insights10.com
We maintain an extensive database comprising
over 30,000 syndicated market research reports
within the pharmaceuticals and healthcare sector,
offering a global, regional, and country-level
perspective. Our services also include the provision
of customized research reports, meticulously
tailored to align with your specific requirements.

47. At Insights10, our extensive report
library spans a diverse range of
categories within the field of life
sciences.
Market Research
Reports across various
categories in healthcare
www. insig hts10. com
www.insights10.com
Digital
Health
Medical
Devices
Healthcare
Services
Rare
Diseases
Clinical
Trials
OTC &
Nutraceuticals
Pharma
(Diseases
& Drugs)

48. Click on the country to see the reports
available
Global Coverage
North America
•US
•Canada
Latin America
•Brazil
•Argentina
•Mexico
•Ecuador
•Venezuela
•Senegal
Europe
•UK
•Germany
•France
•Italy
•Spain
•Russia
•Netherlands
•Sweden
•Romania
•Switzerland
• Poland
• Austria
• Ireland
• Norway
• Denmark
• Belgium
• Portugal
• Ukraine
• Bulgaria
• Finland
APAC
• India
• China
• South Korea
• Japan
• Australia
• Indonesia
• Hong Kong
• New Zealand
• Philippines
• Singapore
• Malaysia
• Thailand
• Vietnam
Middle East
•UAE
•Saudi Arabia
•Turkey
•Lebanon
•Kuwait
•Qatar
Africa
•Egypt
•Kenya
•South Africa
•Algeria
•Nigeria
•Libya
•Tanzania
•Morocco

49. What do our reports cover?
Market Overview
Growth Drivers & Growth Restraints
Epidemiology & Disease type
Market Size & Forecast
Competitive Landscape
Policy & Regulatory Landscape
Reimbursement Scenario
Recent Developments
Market Segmentation Factors Driving Future Growth
1
2
3
4
5
6
7
8
9
10

50. 01 0302 04 05
Define
precise
research
questions
Validate data
through primary
research
interviews
Gather data
through
secondary
research
Forecast
market size
and segment
analysis
Extract key
insights from
the research
findings
06
Compile &
present a
comprehensive
analytical report
Our Research Process

51. Bottom Up Approach
Analyze product or treatment pricing
and reimbursement strategies
Evaluate consumer or patient
demographics and numbers
Predict future market
growth or decline based
on key market trends &
dynamics
Find
final
market size
Top Down Approach
Examine the total healthcare expenditure in
the targeted disease or service domain.
Assess the proportion of spending
allocated to the specific product or
treatment category.
Predict future market
growth or decline
based on key market
trends & dynamics
Find
final
market
size
Data Triangulation & Data Validation

52. 2023
2024-
2030
Report Attribute
Quantitative Units
Pricing and Purchase
Revenue in USD Million/Billion (Mn/Bn)
Our pricing and purchase options are adaptable to
suit the specific scope of work.
Details Time Frame
Base
Year for
estimation
Forecast
Period
Report Scope
Delivery Timeline
Typically, the delivery of the final report falls within a
timeframe of 5 to 7 business days, but the exact
duration may vary depending on the project's scope.
Customization
We are pleased to offer you the option of
customizing the report to align with your specific
research requirements at no extra charge, provided
it falls within the defined scope of the project.

53. We have access to a multitude of highly
dependable data sources, supported by
years of experience that guide us in
discerning which sources are most reliable
and current for the specific information
needed.
Access to credible
data sources for
secondary research
www. insig hts10. com
www.insights10.com
Statistical
Databases
Annual
Reports
Trade
Publications
Online
Databases
Published
Research
Reports
White-
papers
Press
Releases

54. Reliable
Expert Verified
Realistic
Comprehensive
Easy to read
Our reports present data, which is
The report is prepared using a proven methodology and insightful
research
The report is prepared by a team of highly qualified & experienced
research analysts & vetted by our local associates
The report allows you to confidently make smarter business and
strategic decisions based on realistic findings
Covers everything you would need to know about the market
including market size, competitive analysis & much more
You do not have to be a market expert to understand what really is
happening on the market and how it works

55. Yearly Access
(Subscription)
Regulatory
Compliance
Competitive
Intelligence
Conference
Coverage
Full-Time
Engagement
Database Service
& KOL Mapping
Primary Research &
Interviews
Customized Market
Research Reports
Syndicated Market
Research Reports
Our Services

56. “The business decision-making process is no longer as
straightforward as it used to be. It requires insights
generated at the right time, based on reliable data
interpreted in a nuanced manner for each market. We at
Insights10 are building the future of market research and
are committed to providing our clients with the right
intelligence and insights to make business decisions
quickly and efficiently.
Insights10 is a unique platform that combines deep
domain expertise, nuanced data at a country and
functional area level, and years of experience working with
some of the best organizations in the world, generating
insights that provides substantial competitive advantage.”
Dr. Purav Gandhi, Founder & CEO
Click to watch Our Introductory Video here
CEO Speaks

57. Purav is a physician and an
entrepreneur with 12+ years of
experience in Healthcare & Life
Sciences industry spanning across
strategy, market access, health
informatics and RWE, digital health,
analytics and data science. Purav
studied medicine from Gujarat
University and also completed his MBA
from IIM-Kozhikode. Purav started his
career with Deloitte working on strategy
consulting engagements and also co-
founded ConvergeHealth by Deloitte.
Anish has 15+ years of
experience in management
consulting in the Life Sciences
sector, and has worked with
diverse multinational firms in
the US, India, Middle East and
APAC regions. His primary area
of interest is Customer and
Market Strategy, Market
Access, and Digital Health with
special focus on emerging
markets like Africa, Middle East
and APAC.
Dr. Purav Gandhi
Founder & CEO
Anish Swaminathan
Director
Mukesh is an engineering graduate with
an MBA in Marketing. He is a seasoned
healthcare market research &
marketing professional with a
progressive experience of over 20
years in Life Sciences, Healthcare
services, Pharma and Medical Device
sectors. With an in-depth understanding
of primary research, he has conducted
hundreds of interviews of various
stakeholders in pharma & healthcare &
completed several research projects
across life sciences industry.
Ritu has over 6 years of experience in
strategy building, market assessments,
market sizing, and RWE for global MNC
healthcare & biopharma clients across
diff. markets (America, Europe, Africa,
APAC and Middle East). Her areas of
expertise include: Indentifying emerging
trends in life sciences industry,
Competitor landscape assessment,
Disease opportunity assessments etc.
She is a pro in secondary and primary
research with a deep domain expertise
in healthcare sector.
Mukesh Nayak
Head – Marketing & Research
Ritu Baliya
Engagement Manager
Leadership Team

58. @Our Team

59. @Work

60. Beyond Work

61. … and many more
Pi-SM
GmbH
Our Clients

62. I've had the pleasure of availing Insights10’s services several times, and I've always
been impressed by their expertise, professionalism, and dedication to providing us with
the highest quality data and insights. Whether one is looking to launch a new product,
expand into a new market, or better understand one's target customers, Insights10
insures achieving the goals.
Their team of experts has a deep understanding of the healthcare industry, and they use
their knowledge to develop customized research solutions that meet the specific needs
of each client. I highly recommend Insights10 to anyone looking for a reliable and
experienced partner in healthcare market research. They're a valuable asset to any
company that wants to succeed in this dynamic sector.
Sid Panigrahy
Founder-CEO, MediGlobo Inc.,
(Healthcare - Group Company of Omi Holdings, Inc) Tampa, Florida (USA)
What our clients say

63. Dear Insights10 Team, I wanted to thank you all for the great work you conducted
producing the Kenya Medical and Diagnostic Laboratory Service Market Analysis. The
quality of the report was excellent, and you managed to complete it in record time. I was
also impressed by your quick turnaround on the topics discussed as a follow up after the
report's first version; you managed to gather the information required, plus a very good
analysis.
I will definitely consider working with you again if the opportunity arises, and will not
hesitate in recommending you to colleagues working in the field Thank you again for
your professionalism and team work. It was a pleasure working with you.
Lelio Marmora
CEO, The Management Lab, Geneva
Ex. Executive Director, UNITAID
What our clients say

64. Michael Blumberg Youssef Mallat
Wissem Menad
Dr. Robert Ryan
Co Founder GFAU Pty Ltd., Australia
Co Founder – Embi, Optimum Oral care, Australia
Opusline, A part of Accenture, Paris
Senior Manager Segment Marketing
Performance Health,London, UK
Chief Executive Officer, Innova Therapeutics, Inc., USA
We engaged INSIGHTS10 to assist us with our research requirements
for the Oral Care Market sector in Australia. We been very impressed
with the depth and quality of data and equally with the personal
service we experience from the management team on our account.
They understand our business, our challenges and our goals. There is
a real sense of partnership as we continue to work together.
The info you delivered on the European Patient
Support Market with a deep dive into countries
like Spain, Germany, Italy, France, UK and
Belgium, was very useful.
Insights10 has been a great resource for
getting a detailed report on the UK
Physiotherapy Market. Usually I had multiple
sources for getting global reports, but now I
can get in-depth country reports from
Insights10 which has been a game changer.
We were looking for very specific information regarding Abu Dhabi
Oncology Drugs Market. The insights provided by Insights10 is
fantastic and they just took less than three days to deliver the report.
What our clients say

65. Thank You
www. insig hts10. com
www.insights10.com
Email: [email protected]
India: ([phone]
We would be happy to help.
Do you have
any questions?